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1. Introduction
The concept of radiation therapy for the treatment of benign
diseases refers to the use of moderate to high energy ioniz-
ing radiation as part of the treatment of non-malignant, but
not necessarily harmless, diseases. The usefulness of radia-
tion therapy, based on the anti-inflammatory properties of
ionizing radiation, has been long known. Apart from the treat-
ment of intracranial benign tumors, such as meningiomas
and neurinomas, the prevention of cardiovascular resteno-
sis or treatment of skeletal degenerative diseases are, without
doubt, the main fields of action for radiation therapy in benign
conditions. Nonetheless, many other non-cancer entities may
benefit from ionizing radiation therapy treatment. Concerns
about the development of radiation-induced tumors has been
the principal cause of its scant acceptance. Nevertheless,
the efficacy this therapy has demonstrated, as well as the
quality-of-life improvement among patients, far outweighs
the minimum potential risk associated with the therapeutic
use of ionizing radiation.
2. Radiobiological considerations
Radiobiological mechanisms underlying radiation therapy
effects in benign diseases are not fully understood, different
hypotheses have been proposed as an explanation:
Anti-proliferative effect
This mechanism has been used to explain radiation
therapy’s effect on the prevention of heterotopic ossi-
fication following prosthetic replacement or the pre-
vention of keloid or pterygium recurrence following
their removal. Recommended doses are typically around
10 Gy.
Anti-inflammatory effect
Low radiation doses (2–6 Gy at 0.5 Gy/fraction) are especially
efficient in the initial inflammation process, characterized
by the development of vasodilation, edema, and leuko-
cyte infiltration. Vascular endothelial cells play a key role
in this process. This mechanism explains the efficacy of
low radiation therapy doses in the treatment of synovitis,
osteoarthritis, tendonitis, and other processes associated
with inflammation of synovial membranes, leukocyte hyper-
plasia, and lymphocyte infiltration.
Immunomodulatory effect
Radiation therapy’s effect on circulating lymphocytes prob-
ably plays an important role. This effect of radiation
therapy has been proposed for inflammatory conditions
such as Grave’s ophthalmopathy mainly to a modula-
tory effect on immune response. Recommended doses are
not well established, but doses above 10 Gy are generally
administered.
3. Indications
In 2002, the German Working Group on Radiotherapy in Benign
Diseases reported a consensus document in the red journal
which established potential indications for ionizing radiation
therapy under the following conditions:
1. Acute/chronic inflammatory diseases: hidradenitis sup-
purativa, boils, whitlows, and other antibiotic-refractory
infections.
2. Acute/chronic painful degenerative diseases: ten-
donitis and bursitis of different joints, calcaneal spurs,
etc.
3. Soft tissue proliferative disorders: Dupuytren’s Disease,
Ledderhose’s Disease, Peyronie’s Disease, Gorham–Stout
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Disease, prevention of post-surgical recurrence of ptery-
gium or keloids, etc.
4. Functional disorders: Grave’s ophthalmopathy, arteriove-
nous malformations (AVM), age-related macular degener-
ation, persistent lymphatic fistulae, etc.
5. Skin conditions: basalioma, psoriasis resistant to PUVA
treatment, etc.
6. Other conditions: prophylaxis of heterotopic ossification
in hip or other joints following prosthetic replace-
ment, vascular restenosis prophylaxis following dila-
tion and stent implantation, hemangioma, mastocytosis,
Kasabach–Merrit syndrome, etc.
4. Generals considerations for the use of
radiation therapy in benign diseases
Before conducting any ionizing radiation therapy in non-
cancer diseases, a number of considerations should always
be borne in mind:
1. Assessing beforehand the consequences of not providing
treatment and the natural history of the disease.
2. Determining the risk/benefit ratio for each individual
patient, both from radiation therapy and the available
alternatives.
3. Considering radiation therapy if conventional treatments
have not been effective, if the risks from other treatments
are greater than radiation therapy’s inherent risk or if
the potential implications of not providing treatment are
unacceptable.
4. Assessing the long-term risk of using ionizing radiation in
terms of the total dose, fractions, organs at risk, presence
of comorbidities and the patient’s age.
5. Obtaining always the patient’s informed consent, and
make sure the patient has thoroughly understood the
need, purpose and potential risks of the treatment.
6. Selecting as possible the smallest treatment field and the
lowest effective dose.
7. Using multiple treatment fields and beam incidences,
using appropriate shielding and protection.
8. Planning the treatment using the same criteria for quality
and volume definition as used in cancer external beam
radiation therapy (ICRU-50, ICRU-62).
9. Setting an appropriate follow up which allows for the
assessment of both the treatment response and its effi-
cacy as well as the development of late complications.
10. Always advising the patient to obtain a second opinion
and/or treatment options if there is the slightest doubt
about the therapy.
